As we previously reported, the Ontario Court of Appeal affirmed the lower court’s decision dismissing Apotex’s claims against Eli Lilly under the Ontario and English Statutes of Monopolies, Trademarks Act, and common law conspiracy relating to an olanzapine patent. Eli Lilly had successfully obtained an order of prohibition against Apotex relating to Canadian Patent No. 2,041,113, which was later found invalid in a decision involving Novopharm (affirmed on appeal).
On April 27, 2023, the Supreme Court of Canada dismissed Apotex’s application for leave to appeal.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Federal Court dismisses motion to adjourn section 8 trial to complete document production from non-party generics
As previously reported, the Federal Court found Janssen’s Canadian Patent No. 2,661,422 (422 patent)—which relates to treatment of prostate cancer in humans by co-administration of abiraterone acetate...Read More -
FCA finds Teva would directly infringe and induce infringement of Janssen’s paliperidone palmitate patent
As previously reported, the Federal Court found that Teva would directly infringe but not induce infringement of certain claims of Canadian Patent No. 2,655,335 (335 patent) regarding its paliperidone...Read More -
Apotex’s section 8 claim for Apo-Atomoxetine dismissed
On March 30, 2023, the Ontario Superior Court of Justice dismissed Apotex’s claim under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Apo-Atomoxetine (Lilly’s STRA...Read More